Kansanterveyslaitos KTL

Viitteet 1-3 / 3

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Hoye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer : 11 (2006)
Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18

Villa LL; Ault KA; Giuliano AR; Costa RLR; Petta CA; Andrade RP; Brown DR; Ferency A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson S-E; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine : 27-28 (2006)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Villa LL; Costa RLR; Petta CA; Andrade RP; Ault KA; Guiliano AR; Wheeler CM; Koutsky LA; Malm C; Lehtinen M; Skjeldestad FE; Olsson S-E; Steinwall M; Brown DR; Kurman R; Ronnett BM; Stoler MH; Ferenczy A; Harper DM; Tamms GM; Yu J; Lupinacci L; Railkar R; Taddeo FJ; Jansen KU; Esser MT; Sings HL; Saah A; Barr E
Lancet Oncology : 5 (2005)

"Taddeo FJ" - Selaus tekijän mukaan Kansanterveyslaitos KTL